Chairs: Dhanpat Jain (USA) – Rupert Langer (Austria)

1. Are the histologic features of ICI induced esophagitis specific? – Sara Hafezi Bakhtiari (Canada)
2. What are the challenges with PDL1 scoring (CPS/TAP) for esophageal carcinoma? – Catherina Streutker (Canada)
3. What are the challenges of margins evaluation for dysplasia carcinoma in ESD for esophageal neoplasia: Does it even matter? – Mikhail Lisovsky (USA)
4. Is there a need to count Eosinophils in biopsies during follow-up of EOE biopsies during follow-up of EOE? – Suntrea Hammer (USA)
5. Is there any role in sub-typing BE dysplasia: Intestinal vs. foveolar? – Dhanpat Jain (USA)
6. What is the significance of epidermoid metaplasia in the esophagus? – Xuchen Zhang (USA)
7. What are the challenges of evaluation and reporting of p53 in BE for dysplasia? – Ilke Nalbantoglu (USA)
8. What are the advantages and disadvantages of various systems for evaluating post-therapy tumor regression? – Rupert Langer (Austria)
9. Current role of digital pathology and AI in esophageal carcinoma and treatment response? – Bastian Dislich (Switzerland)
10. Updates on WHO classification 6th edition and staging of esophageal carcinoma? – Deyali Chatterjee (USA)
11. What are current and upcoming biomarkers for esophageal carcinomas? – Bella Liu (USA)